Retrospective analysis reveals ASXL1 mutations impact survival in adults with acute myeloid leukemia treated with lower intensity therapy, suggesting risk reassessment.
BACKGROUND: across different contemporary LIT+VEN backbones remains controversial. METHODS: A retrospective analysis in 554 adults with newly diagnosed AML treated with LIT was conducted, stratified by ASXL1 mutation status and treatment backbone. RESULTS: remained independently associated with inferior overall survival. CONCLUSIONS: AML may be more appropriately classified as intermediate risk in the context of LIT+VEN-based therapy, with the depth of impact influenced by the specific LIT backbone.
No takes yet. Share an insight, caveat, or question.
Marvin‐Peek et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: